To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD

A multicenter, randomized, double-blind, vehicle-controlled, parallel group trial to demonstrate the superiority of 0.3% and 1% OPA-15406 ointment to vehicle in pediatric subjects with AD. This trial consists of the 0.3% OPA-15406 group, the 1% OPA-15406 group, and the vehicle group.

Inclusion Criteria:Sex: Either male or female. Age: 2 to 14 years, inclusive (at time of obtaining informed consent).Diagnosis of AD based on the criteria of Hanifin and Rajka (see Appendix 1).Atopic dermatitis affecting ≥5% to ≤40% of BSA (excluding scalp) at the screening and baseline visit.Exclusion Criteria:1. Subjects who defined as AD or contact dermatitis rapid deterioration, within 28 days prior to the baseline visit.